Comparison of PSOX (paclitaxel, oxaliplatin, S-1) and SOX (oxaliplatin, S-1) as postoperative adjuvant chemotherapy for stage II-III gastric cancer
Our findings suggested that adjuvant PSOX chemotherapy offers superior survival benefits compared to the SOX regimen in patients with staged IIIC GC after D2 gastrectomy. The incidence of adverse events with PSOX chemotherapy was comparable to that of SOX chemotherapy.
Authors
- Xin‐En Huang (ORCID: https://orcid.org/0000-0002-9419-9166)
- Zhijun Fang (ORCID: https://orcid.org/0009-0008-8806-6077)
- Jie Cao (ORCID: https://orcid.org/0000-0002-0401-590X)
- Feiyu Wang
- Xiangming Huang
- Yuqing Cao (ORCID: https://orcid.org/0000-0002-1821-1557)
- Song Meng (ORCID: https://orcid.org/0009-0008-2846-1921)
Institutions
- Nanjing University of Chinese Medicine (CN)
- Jiangsu Provincial Academy of Traditional Chinese Medicine (CN)
- Jiangsu Cancer Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1186/s12957-025-03723-3
- Citations
- 4
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Jiangsu Commission of Health
- National Natural Science Foundation of China
- Government of Jiangsu Province